Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? - Wikidata - wikimedia - TriplyDB

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

http://www.wikidata.org/entity/Q34088265

about

Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home setting Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?New perspectives in glioblastoma antiangiogenic therapy Tumor refractoriness to anti-VEGF therapy Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment Broad targeting of angiogenesis for cancer prevention and therapy Targeting the tumor vasculature to enhance T cell activity Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition.The Role of CC-Chemokines in the Regulation of Angiogenesis Pazopanib in the treatment of soft tissue sarcoma Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells Evolving Therapies and FAK Inhibitors for the Treatment of Cancer Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Pazopanib and HDAC inhibitors interact to kill sarcoma cells.Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS.Pazopanib: approval for soft-tissue sarcoma.Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)A review on various targeted anticancer therapies.Blood vessel repair and regeneration in the ischaemic heart A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.Correlation of antiangiogenic, antioxidant and cytotoxic activities of some Sudanese medicinal plants with phenolic and flavonoid contents Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition Nephrotoxicity of recent anti-cancer agents.Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.AECHL-1, a novel triterpenoid, targets tumor neo-vasculature and impairs the endothelial cell cytoskeleton.Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells.Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden.Management of antiangiogenic therapy-induced hypertension.Targeting angiogenesis in metastatic breast cancer Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells Contrasting effects of sunitinib within in vivo models of metastasis.Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS).Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.

P2860

Q23923997-52F46F78-3EC4-4C85-92B8-774552EFCA8C Q26739760-67E977F0-39A4-4324-A255-FE23BE61916E Q26746028-1C858CCC-C8CA-443E-9280-95B932D4246D Q26747678-D19EEFA8-71EB-46F5-9951-3EA1B0541B7C Q26799914-7E8C41B1-40C2-4A62-B43E-49DB4ED35C0C Q27002903-CA54A7A0-9616-45D4-97E4-1AA049B67AFC Q27026329-E42855BD-6CB0-45B8-B7FA-4C942247EB56 Q27329647-0B54B6F7-55A1-4B7F-B86B-81D844EB375B Q28077024-2F4CC6E8-E62F-42E7-BEB3-6700D5FDFFDE Q28269229-AE3A4E21-5790-4721-AD65-310432496F5B Q28484299-885C4AFB-0788-4581-8069-7113C0B77993 Q28972291-F834E93F-EA3F-40B0-8E85-ADEEE5EECE1A Q33422258-B1792456-2FBB-47EE-8987-860A6BD27C00 Q33631472-035DD97A-46C0-4602-B339-653FB2F0AA21 Q33826472-1856DDB2-50B8-4714-B910-96F651460F70 Q33885782-954CDB81-A8DF-4E81-B422-43B598CD84F8 Q34077272-B680AAE2-1055-4677-B8D5-EE05D54F840A Q34164735-0DE13F96-9D44-456A-B54A-6322A8BF38EE Q34304413-94A354F1-6CBA-4084-8F9E-D6EC1253F8E3 Q34363435-C1207BB8-1C7E-4F45-AB83-667620E08D4A Q34410771-26396B85-CCE5-4ADD-8390-D9EBCC7A24EA Q34458617-DE83313B-1EE4-4AEE-9356-39AD2B7E151B Q34522228-F664ADF5-8688-403D-BCF6-3D22D96EA5DB Q35310741-4C06F604-A20B-4FE9-874E-CB84EE4D449A Q35534962-3519D482-D5F7-4F1C-87A8-54FFA0EBE8E4 Q35634179-43E8E717-C491-40D1-9914-AA9FF124AD3F Q35703000-BCDCE1B6-B3D5-455C-9221-35FCBBA9D303 Q35757079-55054FD1-6003-4EDC-B06D-B11F9CD67D02 Q35858012-D5492689-24B4-4084-8208-237C8982B40E Q35863135-40ED91A3-C70A-4419-B136-41150087DF65 Q35875753-3F1C4D07-AA57-4A78-8EF3-2E654DE33875 Q36067203-2E28BF9C-256D-4A91-A752-287A0FDDC005 Q36103833-F11A386D-6676-4EF1-AA4C-934D7A1D1A65 Q36170252-671AFB9F-6E2E-41D8-ADC3-6D5F4C726244 Q36182795-27C8FF6B-1A5B-4E37-B722-B73103CBE8EB Q36378963-4CAFFE0D-828C-4221-8154-5269C848F529 Q36394262-F42CBC40-32F4-4E7B-AE98-91FDB0240F84 Q36472317-B75E176A-A894-4AB8-B715-71F12B2C65FF Q36777194-A0FA2079-39F1-4E99-80BD-FB8C125BA374 Q36799684-E5E17BE5-D6A8-470D-A6FE-5788623FD1A0

P2860

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

http://www.wikidata.org/entity/Q34088265

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

@ast

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

@en

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

@nl

type

label

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

@ast

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

@en

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

@nl

prefLabel

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

@ast

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

@en

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

@nl

P1433

Q34088265-0FE78E01-567D-450E-98C9-FE10D1B35CA1

P1476

Q34088265-12F9685A-4A6C-4C1D-9BE5-5553AB6EA4F2

P2093

Q34088265-79F789F6-3113-4D91-B56A-D9BCB49A8A4F

Q34088265-9EF8EBF7-3C46-4E51-9C43-F0A972377243

P2860

Q34088265-01E0B57C-2EEB-435C-B7A4-A1CE0FC89DE6

Q34088265-0257FE1E-1913-48BC-BD84-85ACD1FB53E6

Q34088265-02EBBCCE-74BD-4154-AF7A-8D383F0C8E4F

Q34088265-038E55D5-CB80-4CB0-9D6B-AD6E5F779611

Q34088265-07AF32AF-0FB7-4282-B806-459A32C9EA1A

Q34088265-0BA151E0-2BBA-4D20-957A-A211E1AB05F0

Q34088265-0C895D00-7775-450F-922F-76AD5408E4F1

Q34088265-0C9786C0-1C7D-4DFF-8347-A052D64236FB

Q34088265-0F73BF48-BC54-4C78-A03C-F293DB15D989

Q34088265-150C8043-8E6A-4A99-9D0E-0A2E7E825B58

P2888

Q34088265-1D619E81-3046-4391-AEAB-A6FFC326F776

P304

Q34088265-421A44D9-3C13-4268-ACE5-56E9FECE4C7E

P31

Q34088265-77C5BF0A-B75A-431E-939F-F6B8DD30EEA1

Q34088265-8FFF49E7-0678-494B-97E1-CC0454A502B7

P356

Q34088265-EC639969-A05E-4783-A714-7ACA43981997

P433

Q34088265-7FF5DC50-4D12-461D-9871-14CAA71CFAA2

P478

Q34088265-4FB35ED7-39D4-44E9-A132-EFD2489B5FAD

P577

Q34088265-5BC57B3B-C1C4-4D3C-BB1A-BE27FF82180F

Q34088265-D9B146E4-E377-4689-B6A3-142F8F6881B9

P5875

Q34088265-F1D98332-213F-4C2E-AB36-41991E31A29B

P698

Q34088265-8682403C-2AC9-4CB8-AACF-F4C13C34832F

P921

Q34088265-50BF8E3B-E4D8-4F2B-96AF-4F8E38BDAE55

Q34088265-89FEE75E-F6A3-4597-8765-B824A83290B6

P932

Q34088265-EB23FCD5-2D01-4E4D-AF4E-60071A2BA40F

P356

S10456-009-9160-6

P1433

P1476

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

@en

P2093

Henk M W Verheul

http://www.w3.org/2001/XMLSchema#string

Kristy J Gotink

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells

The protein kinase complement of the human genome

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis.

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Modes of resistance to anti-angiogenic therapy

VEGF inhibition and renal thrombotic microangiopathy

AKT/PKB signaling: navigating downstream

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

P2888

s10456-009-9160-6

P304

1-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10456-009-9160-6

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40689914

http://www.w3.org/2001/XMLSchema#string

P698

20012482

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

P932

2845892

http://www.w3.org/2001/XMLSchema#string